Cannabidiol News March 8 2019
The USPTO has issued a new patent, No. 10,213,390, to Zynerba Pharmaceuticals (NASDAQ:ZYNE) covering the use of its cannabidiol transdermal gel (ZYN002) to treat Fragile X syndrome, an inherited disorder characterized by learning disabilities and cognitive impairment. Shares are up 17% premarket on increased volume.
At Zynerba Pharmaceuticals, our team is dedicated to developing next-generation transdermally-delivered cannabinoid therapeutics for patients affected by rare and near-rare neuropsychiatric conditions. Often, these diseases have few, if any, treatment options and can leave patients and their families feeling helpless and alone. Zynerba is committed to developing breakthrough therapies to transform the quality of lives of patients and their families as they battle these conditions.
The Drug Enforcement Agency
(DEA) announced in August 2016 that marijuana will remain a Schedule I drug which means that it has no currently accepted medical use in the United States, it lacks an accepted safety use under medical supervision and it has a high potential for abuse. This decision was based, in part, on the conclusion by the Department of Health and Human Services that marijuana has no “currently accepted medical use” and there are “no adequate and well-controlled studies proving efficacy.”
|United States Patent||6,630,507|
|Assignee:||The United States of America as represented by the Department of Health and Human Services (Washington, DC)|
AGRICULTURE IMPROVEMENT ACT OF 2018
SEC. 297A. DEFINITIONS.
“In this subtitle: “(1) Hemp.–The term `hemp’ means the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta- 9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis. “(2) Indian tribe.–The term `Indian tribe’ has the meaning given the term in section 4 of the Indian Self-Determination and Education Assistance Act (25 U.S.C. 5304).
SEC. 10114. INTERSTATE COMMERCE. (a) Rule of Construction.–Nothing in this title or an amendment made by this title prohibits the interstate commerce of hemp (as defined in section 297A of the Agricultural Marketing Act of 1946 (as added by section 10113)) or hemp products. (b) Transportation of Hemp and Hemp Products.–No State or Indian Tribe shall prohibit the transportation or shipment of hemp or hemp products produced in accordance with subtitle G of the Agricultural Marketing Act of 1946 (as added by section 10113) through the State or the territory of the Indian Tribe, as applicable.
The Hemp Farming Act provisions in the Agriculture Improvement Act of 2018 (2018 Farm Bill) signed into law on December 20, 2018:
· Removed hemp and its derivatives from the list of controlled substances;
· Established hemp as a legal agricultural commodity;
· Authorized the production, consumption, and sale of hemp and hemp-derived products in the United States, consistent with other federal laws, like the Food, Drug and Cosmetic Act;
· Authorized the use of federal funds to support hemp research under the National Agricultural Research, Extension National Agricultural Research, Extension, and Teaching Policy Act of 1977 and the Critical Agricultural Materials Act; and
· Explicitly established the protection of the interstate commerce of hemp or hemp products and further prevented states and tribal governments from prohibiting the transportation of hemp or hemp products through the State or the territory of the Indian Tribe.
Section 297D(c)(p. 434): Nothing in the new law affects the FDA’s authority under the Food, Drug, and Cosmetic Act or the Public Health Service Act.
Section 12619 (p. 540): Hemp is removed from the definition of “marihuana,” and THC found in hemp is excluded from the definition of a controlled substance.
Section 297A (p. 429) Defines hemp as all parts of the plant less than 0.3% THC, including “derivatives,” “extracts” and “cannabinoids” and permits hemp production in all states and territories.
p. 739: “While states and Indian tribes may limit the production and sale of hemp and hemp products within their borders, the Managers, in Section 10122, agreed to not allow such states and Indian tribes to limit the transportation or shipment of hemp or hemp products through the state or Indian territory.
The Wyoming Tribune Eagle reports that Gordon signed House Bill 171 on Wednesday. The legislation sponsored by Republican Rep. Bunky Loucks, of Casper, allows for hemp to be grown in the state, along with the production and sale of hemp-based products, including ones containing CBD oil.